Sam Fazelli

And then, of course, Novo never went down that road.

I'm always wondering where they are with this rule because you can't just go and make something somewhere and say, here we go, we've got a product.

The whole point of the FDA is to be regulating efficacy and safety particularly.

And HIMSS product had never been through any of those tests or looked at by the FDA.

So I'm really glad to see this happening and the rule of law coming back in.

It could be a bigger reprieve if they decide to also not continue with the injectable version.

That's a lot easier.

There was a period where they were allowed to because there was lack of supply.

Then the FDA, I think, didn't do much when supply came back on and the compounders still carried on.

We were always wondering where they are with this rule because you can't just go and make something somewhere and say, here we go, we've got a product.

The whole point of the FDA is to be regulating efficacy and safety particularly.

And his product had never been through any of those tests.

It could be a bigger reprieve if they decide to also not continue with the injectable version.

That's a lot easier.

There was a period where they were allowed to because there was lack of supply.

Then the FDA, I think, didn't do much when supply came back on and the compounders still carried on.

It could be a bigger reprieve if they decide to also not continue with the injectable version.

That's a lot easier.

There was a period where they were allowed to because there was lack of supply.

Then the FDA, I think, didn't do much when supply came back on and the compounders still carried on.